A New Strategy to Uncover the Anticancer Mechanism of Chinese Compound Formula by Integrating Systems Pharmacology and Bioinformatics

Table 3

KEGG pathway analysis.

Pathway Name	#Gen	Uniprot name (corresponding gene set)	Statistics
Cell cycle	24	CDK2 CDK7 CDKN1A CDKN1B CHEK1 MCM5 MDM2 PCNA ATY CCND1 BUB1B TP53 CCNA2 CCNA1 CCNB1 CCND3 CCNE1 CCNH CCNB2 CCNE2 CDK1 CDC6 CDC20 CDC25C	C=124; O=24; E=1.59; R=15.09; rawP=0e+00; adjP=0e+00
Pathways in cancer	31	CDK2 CDKN1A CDKN1B CKS1B CKS2 EGF EGFR AKT1 FOS GSTP1 HSP90AA1 IL6 AR JUN MDM2 MMP1 MMP2 PIK3CG PPARG MAPK8 PTGS2 CCND1 BCL2 RXRA RXRB TP53 VEGFA VEGFC CCNA1 CCNE1 CCNE2	C=397; O=31; E=5.09; R=6.09; rawP=0e+00; adjP=0e+00
p53 signaling pathway	15	CDK2 CDKN1A CHEK1 MDM2 MDM4 SERPINE1 ATR CCND1 TP53 CCNB1 CCND3 CCNE1 CCNB2 CCNE2 CDK1	C=69; O=15; E=0.88; R=16.95; rawP=4.22e-15; adjP=3.78e-13
AGE-RAGE signaling pathway in diabetic complications	17	CDKN1B COL1A1 MAPK14 AKT1 F3 IL6 JUN MMP2 NOS3 SERPINE1 PIK3CG MAPK8 CCND1 BCL2 TNF VEGFA VEGFC	C=101; O=17; E=1.3; R=13.13; rawP=5e-15; adjP=3.78e-13
Prostate cancer	16	CDK2 CDKN1A CDKN1B EGF EGFR AKT1 GSTP1 HSP90AA1 AR MDM2 PIK3CG CCND1 BCL2 TP53 CCNE1 CCNE2	C=89; O=16; E=1.14; R=14.02; rawP=1.15e-14; adjP=7e-13
Endocrine resistance	16	CDKN1A CDKN1B MAPK14 EGFR AKT1 ESR1 ESR2 FOS JUN MDM2 MMP2 PIK3CG MAPK8 CCND1 BCL2 TP53	C=98; O=16; E=1.26; R=12.73; rawP=5.64e-14; adjP=2.85e-12
Hepatitis B	18	CDK2 CDKN1A CDKN1B AKT1 FOS IL6 JUN PCNA PIK3CG MAPK8 CCND1 BCL2 TNF TP53 CCNA2 CCNA1 CCNE1 CCNE2	C=146; O=18; E=1.87; R=9.62; rawP=2.03e-13; adjP=8.77e-12
PI3K-Akt signaling pathway	25	BCL2L11 CDK2 CDKN1A CDKN1B CDC37 COL1A1 EGF EGFR AKT1 FLT1 HSP90AA1 IL6 KDR MDM2 NOS3 PIK3CG CCND1 BCL2 RXRA TP53 VEGFA VEGFC CCND3 CCNE1 CCNE2	C=341; O=25; E=4.37; R=5.72; rawP=4.23e-13; adjP=1.6e-11
Small cell lung cancer	14	CDK2 CDKN1B CKS1B CKS2 AKT1 PIK3CG PTGS2 CCND1 BCL2 RXRA RXRB TP53 CCNE1 CCNE2	C=86; O=14; E=1.1; R=12.7; rawP=2.52e-12; adjP=8.48e-11
FoxO signaling pathway	15	BCL2L11 CDK2 CDKN1A CDKN1B MAPK14 EGF EGFR AKT1 IL6 MDM2 PIK3CG MAPK8 CCND1 CCNB1 CCNB2	C=134; O=15; E=1.72; R=8.73; rawP=1.03e-10; adjP=3.12e-09

The following statistics were listed in the row: C: the number of reference targets in the category; O: the number of targets in both the gene set and the category; E: the expected number in the category; R: ratio of enrichment; rawP: p value upon hypergeometric test; and adjP: p value adjusted by the multiple test adjustment.